Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-RRMM
jRCT2051210043Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of iberdomide, daratumumab, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Dec 2022; status: active, not recruiting.
02
Drugs
iberdomidedaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051210043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210043.